Objective To investigate the clinical and imaging features of right-side non-thrombotic iliac vein compression syndrome(NIVCS),and to evaluate the efficacy of endovascular treatment.Methods The clinical data and imaging materials of lower extremity venography from January 2019 to February 2024 in Affiliated Nanjing Gaochun People's Hospital,Jiangsu University were retrospectively analyzed.The patients with clinically diagnosed right-side NIVCS who received endovascular treatment were selected for this study.The clinical features and imaging findings,technical success rate,postoperative clinical improvement,and stent patency rate were analyzed.Results The median follow-up time was 30.2 months(3-58 months).A total of 24 patients with right-side NIVCS(aged 42-73 years)were enrolled in this study.Of the 24 patients,22(91.7％)were male and only 2(8.3％)were female,the proportion of male was significantly higher than that of female(P＜0.001).According to Clinical Etiologic Anatomic Pathophysiologic(CEAP)grading,14 patients were of grade C3,9 patients were of grade C,and one patient was of grade C.Imaging examination showed that the most frequent site of compression was the proximal end of the external iliac vein(15/24,62.5％),the second frequent site of compression was the proximal part of the common iliac vein bifurcation(5/24,20.8％).The most common external pressure structure was the internal and external iliac arteries(14/24,58.3％),the second common external pressure structure was external iliac artery and sacrum(5/24,20.8％).The technical success rate was 100％,and only one stent was implanted in each patient(diameter of 12-14 mm and length of 80-90 mm).The most commonly used stent was the Smart control(19/24,79.2％).During follow-up period,the remission rate of edema was 85.7％(18/21),the ulcer healing rate was 100％(1/1),and all stents remained patent.Conclusion Right-side NIVCS is more commonly seen in male patients.Because the compression site is usually located at the distal end of iliac vein,thus,the implanted stent may rarely affect blood flow in the contralateral iliac vein.Therefore,endovascular treatment is a safe and effective method for right-side NIVCS.

Objective To investigate the clinical application value of serum exosomal miR-552 and miR-221 in the diagnosis and prog-nosis of gastric cancer.Methods 133 patients diagnosed with gastric cancer in the Department of Gastrointestinal Surgery,Suqian First People's Hospital from January to December 2019 were selected as the gastric cancer group,108 patients with chronic gastritis as the benign lesion group,and 94 healthy individuals undergoing physical examination as the healthy control group.Their blood samples were collected,and serum exosomes were extracted.The expression levels of miR-552 and miR-221 in serum exosomes were detected by real-time fluorescence quantitative PCR(qRT-PCR).The receiver operating characteristics(ROC)curve was used to assess the di-agnostic efficacy of miR-552 and miR-221 alone and in combination for gastric cancer.The correlations of serum exosomal miR-552 and miR-221 levels with the clinicopathological parameters of gastric cancer patients were further analyzed,and the survival curve was used to evaluate the prognosis of gastric cancer patients.Results The expression levels of serum exosomal miR-552 and miR-221 in gastric cancer patients,benign lesion patients,and healthy controls showed statistically significant differences(FmiR-552=296.271,FmiR-221=249.638,P＜0.01)and a decreasing trend.The analysis results of the ROC curve showed that the combined detection of serum exosom-al miR-552 and miR-221 for the diagnosis of gastric cancer had an area under the ROC curve(AUCROC)of 0.901,a sensitivity of 89.50%,and a specificity of 96.90%,all significantly higher than the detection of miR-552(sensitivity of 88.7%and specificity of 87.2%)and miR-221(sensitivity of 83.5%and specificity of 85.1%)alone(P＜0.05).The expression levels of serum exosomal miR-552 and miR-221 were related to tumor size,TNM staging,invasion depth,and lymph node metastasis(P＜0.05).The analysis results of the survival curve revealed that gastric cancer patients with high expression of serum exosomal miR-552 and miR-221 had sig-nificantly shorter survival time than those with low expression(χ2miR-552=30.657,χ2miR-221=38.251,P＜0.05).Conclusion Serum exo-somal miR-552 and miR-221 have high diagnostic efficacy for gastric cancer and may serve as novel biological markers for the diagnosis and prognosis evaluation of gastric cancer.

Objective To investigate the clinical application value of serum exosomal miR-552 and miR-221 in the diagnosis and prog-nosis of gastric cancer.Methods 133 patients diagnosed with gastric cancer in the Department of Gastrointestinal Surgery,Suqian First People's Hospital from January to December 2019 were selected as the gastric cancer group,108 patients with chronic gastritis as the benign lesion group,and 94 healthy individuals undergoing physical examination as the healthy control group.Their blood samples were collected,and serum exosomes were extracted.The expression levels of miR-552 and miR-221 in serum exosomes were detected by real-time fluorescence quantitative PCR(qRT-PCR).The receiver operating characteristics(ROC)curve was used to assess the di-agnostic efficacy of miR-552 and miR-221 alone and in combination for gastric cancer.The correlations of serum exosomal miR-552 and miR-221 levels with the clinicopathological parameters of gastric cancer patients were further analyzed,and the survival curve was used to evaluate the prognosis of gastric cancer patients.Results The expression levels of serum exosomal miR-552 and miR-221 in gastric cancer patients,benign lesion patients,and healthy controls showed statistically significant differences(FmiR-552=296.271,FmiR-221=249.638,P＜0.01)and a decreasing trend.The analysis results of the ROC curve showed that the combined detection of serum exosom-al miR-552 and miR-221 for the diagnosis of gastric cancer had an area under the ROC curve(AUCROC)of 0.901,a sensitivity of 89.50%,and a specificity of 96.90%,all significantly higher than the detection of miR-552(sensitivity of 88.7%and specificity of 87.2%)and miR-221(sensitivity of 83.5%and specificity of 85.1%)alone(P＜0.05).The expression levels of serum exosomal miR-552 and miR-221 were related to tumor size,TNM staging,invasion depth,and lymph node metastasis(P＜0.05).The analysis results of the survival curve revealed that gastric cancer patients with high expression of serum exosomal miR-552 and miR-221 had sig-nificantly shorter survival time than those with low expression(χ2miR-552=30.657,χ2miR-221=38.251,P＜0.05).Conclusion Serum exo-somal miR-552 and miR-221 have high diagnostic efficacy for gastric cancer and may serve as novel biological markers for the diagnosis and prognosis evaluation of gastric cancer.

The chloroplast genome encodes many key proteins involved in photosynthesis and other metabolic processes, and metabolites synthesized in chloroplasts are essential for normal plant growth and development. Root-UVB (ultraviolet radiation B)-sensitive (RUS) family proteins composed of highly conserved DUF647 domain belong to chloroplast proteins. They play an important role in the regulation of various life activities such as plant morphogenesis, material transport and energy metabolism. This article summarizes the recent advances of the RUS family proteins in the growth and development of plants such as embryonic development, photomorphological construction, VB6 homeostasis, auxin transport and anther development, with the aim to facilitate further study of its molecular regulation mechanism in plant growth and development.
Female ; Pregnancy ; Humans ; Ultraviolet Rays ; Biological Transport ; Chloroplasts/genetics* ; Embryonic Development ; Plant Development/genetics*

Objective In this study,the diversity of the TCR β chain CDR3 in peripheral blood of patients with different typical Traditional Chinese Medicine(TCM)syndromes of liver cirrhosis was analyzed by immune repertoire sequencing,the material basis and regularity of the syndromes of liver cirrhosis was discussed.Methods 20 patients with cirrhosis,including liver and gallbladder damp heat(LGHD),liver depression and spleen deficiency(LDSD),and liver and kidney yin deficiency(LKYD)were enrolled into case group,and 10 healthy patients were used as the healthy control group.DNA was extracted from peripheral blood samples,and multiplex PCR amplification of TCR β chain CDR3 was performed,followed by high-throughput sequencing of the products to analyze the diversity of the TCR β chain CDR3.Results The nt sequence numbers unique to CDR3 and aa sequence numbers unique to CDR3 of LDSD between liver cirrhosis syndromes were less than LKYD(P<0.05).Clonality,Pielous,Shannon.Index and DE50 of LGHD and LKYD had significant differences(P<0.05)between two groups,as well as the frequency of multiple fragments in V and J regions and V-J gene recombination of LGHD vs.LDSD,LGHD vs.LKYD,and LKYD vs.LDSD,respectively(P<0.05).LGHD vs.LDSD,TRBV21-1,TRBV12-4,TRBV11-1 subtype and 7 pairs of V-J recombination have statistical differences(P<0.05).LGHD vs.LKYD,TRBV10-2,TRBV7-6,TRBV5-8 subtypes and 30 pairs of V-J recombination were statistically different(P<0.05).LDSD vs.LKYD,there were statistical differences between TRBJ1-5 subtype and 18 pairs of V-J recombination(P<0.05).Conclusions The present study was conducted to find that the diversity of TCR CDR3 in liver cirrhosis syndrome is significantly different and conforms to the regularity of syndrome from excess to deficiency by explore the immunological characteristics of different TCM syndromes of liver cirrhosis,and to provide new support for the objective basis of"combination of disease and TCM syndrome"and"diagnosis and treatment".We explored the different expression patterns and specificity of adaptive immune gene rearrangement in patients with different TCM syndromes to identify different expression patterns and specific markers of adaptive immune gene rearrangements of typical TCM syndromes in liver cirrhosis.

Objective To investigate the clinical application value of contrast-enhanced chest CT in the detection of responsible vessels for hemoptysis before selective arterial embolization(SAE).Methods The clinical data of 74 patients with hemoptysis trea-ted with interventional therapy and preoperative contrast-enhanced chest CT and digital subtraction angiography(DSA)were ana-lyzed retrospectively.The responsible vessels were identified and then embolized via angiography.The detection of the responsible vessels via preoperative contrast-enhanced chest CT was analyzed.The patients were followed up to observe the efficacy and compli-cations,and the influencing factors of interventional efficacy and recurrence were analyzed.Results A total of 245 responsible ves-sels were detected by preoperative contrast-enhanced chest CT,including bronchial arteries(n=178),ectopic bronchial arteries(n=10)and non-bronchial systemic artery(NBSA)(n=57),which could accurately show the anatomical information of responsible vessels.A total of 4 posterior intercostal arteries were missed.The diagnostic accuracy was 98.4％(245/249).All patients were followed up for 12 to 25.6 months.The immediate hemostasis rate was 93.2％(69/74)and the effective rate was 79.7％(59/74),respectively.The factors affecting the efficacy were bronchial artery to pulmonary circulation fistula,pleural thickening at the bleeding site,and underly-ing lung disease.Among the 59 patients with effective treatment,underlying lung disease was the influencing factor for postoperative recurrence.Conclusion Contrast-enhanced chest CT can provide anatomical information about the responsible vessels for interven-tional therapy of hemoptysis,improving surgical efficiency and reducing the recurrence rate of hemoptysis.

ObjectiveTo adapt the Stanford Expectations of Treatment Scale（SETS） into Chinese（C-SETS） and test the feasibility， validity and reliability of its application in patients with diarrhea-predominant irritable bowel syndrome（IBS-D） with liver-constraint and spleen-deficiency syndrome treated with traditional Chinese medicine（TCM）. MethodsWe obtained authorisation from the developer of the SETS， and followed the principle of "two-way translation" to translate the SETS by literal translation and back translation to form the C-SETS. Ninety-six IBS-D patients with liver-constraint and spleen-deficiency syndrome were enrolled as respondents and filled out C-SETS before receiving treatment； the feasibility was assessed by the recall rate， completion rate and the duration of filling out the scale； the reliability was assessed by Cronbach's α； the structural validity was assessed by exploratory and confirmatory factor analysis， and the content validity was assessed by correlation analysis. ResultsThe C-SETS consists of 10 items， with the 1st， 3rd， and 5th rating items constituting the Positive Expectations subscale， and the 2nd， 4th， and 6th rating items constituting the Negative Expectations subscale， each of which is rated on a 7-point Likert Scale. The recall of C-SETS was 100%（96/96）， the completion rate was 89.58%（86/96）； Cronbach's α for the Positive and Negative Treatment Expectations subscales were 0.845 and 0.854， respectively； exploratory factor analysis showed that the coefficient of commonality for all six entries was larger than 0.4， and that the six entries could be used by both factors to explain 77.092% of the total variance； validation factor analysis showed that the goodness-of-fit index， comparative fit index， root mean square of approximation error， canonical fit coefficient， and chi-square degrees of freedom ratio took the values of 0.943， 1.003， 0， 0.943， and 0.626， respectively； and the results of Spearman's analysis suggested that the C-SETS had good content validity. ConclusionThe C-SETS has well feasibility， reliability， and validity， which initially proves that it can be used as a tool to assess the treatment expectation of patients with IBS-D with liver-constraint and spleen-deficiency syndrome before receiving TCM treatment.

At present， the process and methodology of patient guidelines （PGs） development varies greatly and lacks systematic and standardised guidance. In addition to the interviews with PG developers， we have sorted out the relevant methodology for the adaptation and development of existing clinical practice guideline recommendations and facilitated expert deliberations to achieve a consensus， so as to finally put forward a proposal for guidance on the process and methodology for the development of PGs. The development of PGs can be divided into the preparation stage， the construction stage， and the completion stage in general， but the specific steps vary according to the different modes of development of PGs. The development process of Model 1 is basically the same as the patient version of the guideline development process provided by the International Guidelines Network， i.e.， team formation， screening of recommendations， guideline drafing， user testing and feedback， approval and dissemination. The developer should also first determine the need for and scope of translating the clinical practice guideline into a patient version during the preparation phase. Model 2 adds user experience and feedback to the conventional clinical practice guideline development process （forming a team， determining the scope of the PG， searching， evaluating and integrating evidence， forming recommendations， writing the guideline， and expert review）. Based on the different models， we sort out the process and methods of PG development and introduce the specific methods of PG development， including how to identify the clinical problem and how to form recommendations based on the existing clinical practice guidelines， with a view to providing reference for guideline developers and related researchers.

Objective To elucidate the biological basis of liver-gallbladder damp-heat syndrome(LGDHS)within the framework of traditional Chinese medicine(TCM)as a complementary diagnostic and therapeutic approach in chronic hepatitis B(CHB).Methods CHB patients and healthy volunteers were enrolled from Shuguang Hospital Affili-ated to Shanghai University of Traditional Chinese Medicine between August 21,2018 and December 31,2020.They were divided into three groups:healthy group,LGDHS group,and latent syndrome(LP)group.Proteomic analysis using isobaric tags for relative and absolute quantitation(iTRAQ)was performed to identify differentially expressed proteins(DEPs).Metabolomic profiling via ultra-performance liquid chromatography-tandem mass spec-trometry(UPLC-MS/MS)was applied to serum samples to detect differentially regulated metabolites(DMs).Kyoto Encyclopedia of Genes and Genomes(KEGG)and Gene Ontology(GO)enrichment were employed to explore dysregulated pathways.Principal component analysis(PCA)and orthogonal partial least squares discriminant analysis(OPLS-DA)were utilized to visualize group separation and identify key metabolites and proteins contributing to LGDHS differentiation.Receiver operating characteristic(ROC)curve analysis evaluated the diagnostic performance of key biomarkers,while logistic regression models assessed their predictive accuracy.P values were corrected for multiple tests using the Benjamini-Hochberg method to control the false discovery rate(FDR).Validation of potential biomarkers was con-ducted using independent microarray data and real-time quantitative polymerase chain reac-tion(RT-qPCR).Results A total of 150 participants were enrolled,including healthy group(n=45),LGDHS group(n=60),and LP group(n=45).254 DEPs from proteomics data and 72 DMs from metabolomic profiling were identified by PCA and OPLS-DA.DEPs were mainly enriched in immune and complement pathways,while DMs involved in amino acid and energy metabolism.The integrated analysis identified seven key biomarkers:α1-acid glycoprotein(ORM1),asparagine synthetase(ASNS),solute carrier family 27 member 5(SLC27A5),glu-cosidase Ⅱ alpha subunit(GANAB),hexokinase 2(HK2),5-methyltetrahydrofolate-homocys-teine methyltransferase(MTR),and maltase-glucoamylase(MGAM).Microarray validation confirmed the diagnostic potential of these genes,with area under the curve(AUC)values for ROC analysis ranging from 0.536 to 0.759.Among these,ORM1,ASNS,and SLC27A5 showed significant differential ability in differentiating LGDHS patients(P=0.016,P=0.035,and P<0.001,respectively),with corresponding AUC of 0.749,0.743,and 0.759,respectively.A logis-tic regression model incorporating these three genes demonstrated an AUC of 0.939,indicat-ing a high discriminatory power for LGDHS.RT-qPCR further validated the differential ex-pression of ORM1 and SLC27A5 between LGDHS and LP groups(P=0.011 and P=0.034,re-spectively),with ASNS showing a consistent trend in expression(P=0.928).Conclusion This study integrates multi-omics approaches to uncover the molecular mecha-nisms underlying LGDHS in CHB.The identification of biomarkers ORM1,ASNS,and SLC27A5 offers a solid basis for the objective diagnosis of LGDHS,contributing to the stan-dardization and modernization of TCM diagnostic practices.

Increased intestinal barrier permeability, leaky gut, has been reported in patients with autism. However, its contribution to the development of autism has not been determined. We selected dextran sulfate sodium (DSS) to disrupt and metformin to repair the intestinal barrier in BTBR T⁺tf/J autistic mice to test this hypothesis. DSS treatment resulted in a decreased affinity for social proximity; however, autistic behaviors in mice were improved after the administration of metformin. We found an increased affinity for social proximity/social memory and decreased repetitive and anxiety-related behaviors. The concentration of lipopolysaccharides in blood decreased after the administration of metformin. The expression levels of the key molecules in the toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88)-nuclear factor kappa B (NF-κB) pathway and their downstream inflammatory cytokines in the cerebral cortex were both repressed. Thus, "leaky gut" could be a trigger for the development of autism via activation of the lipopolysaccharide-mediated TLR4-MyD88-NF-κB pathway.
Mice ; Animals ; NF-kappa B ; Myeloid Differentiation Factor 88/metabolism* ; Lipopolysaccharides/pharmacology* ; Toll-Like Receptor 4/metabolism* ; Autistic Disorder/metabolism* ; Signal Transduction/physiology*